Lung Cancer (ALK Fusion): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 47-year-old female light former smoker with no significant past medical history. She presented with non-productive cough, which was unabated by two rounds of antibiotics for presumed community acquired pneumonia. She also has pleuritic left sided chest pain, 5/10. CT scan of the chest and abdomen revealed a LLL lesion, pathologically enlarged lymphadenopathy (left mediastinal, left hilar, and right supraclavicular), and numerous liver lesions. Brain MRI did not reveal any intracranial disease. CT guided biopsy of a  LLL lesion revealed NSCLC,"adenosquamous" histology.

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.
 
Learning Objectives
1.    Describe the testing modalities used to detect ALK rearrangements
2.    Discuss first line therapy options for patients with ALK+ lung cancer
3.    Review resistance mechanisms and second line therapies

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on August 23, 2020. Participants must complete all necessary course components by this date to receive credit.